Home Alzheimer’s Disease Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC

Frontline treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression ≥ 1% or < 1%, according to updated results from part 1 of the phase III Checkmate 227 trial presented at the 2020 ASCO Virtual Scientific Program.

“Based on these results, we note that the combination of nivolumab and ipilimumab, which is now approved by the United States FDA, is a novel chemotherapy-sparing first-line treatment approach for advanced-stage non-small-cell lung cancer,” Suresh S. Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, said during his presentation.

After a median follow-up of 43.1 months, patients with PD-L1 ≥ 1% had a 21% and 10%, respectively, reduced risk for death when treated with nivolumab…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments